Introduction
Material and methods
Patients
Treatment selection criteria
Neoadjuvant or adjuvant therapy
Follow-up
Statistical analysis
Results
Clinical characteristics of MSSCC patients
Variable | n (%) | Median OS | OS | P value | DFS | P value |
---|---|---|---|---|---|---|
Total | 98 (100) | 23 (3–120) | 35.70% | 28.60% | ||
Sex | 0.904 | 0.464 | ||||
Female | 23 (23.5) | 26 (3–98) | 39.10% | 34.80% | ||
Male | 75 (76.5) | 17 (3–120) | 34.70% | 26.70% | ||
Age | 0.329 | 0.448 | ||||
≤55 | 38 (38.8) | 32 (3–120) | 36.80% | 28.30% | ||
>55 | 60 (61.2) | 17.5 (3–120) | 35.00% | 27.90% | ||
Smoking | 0.038* | 0.342 | ||||
No | 31 (31.6) | 33 (5–120) | 51.60% | 32.30% | ||
Yes | 67 (68.4) | 19 (3–98) | 28.40% | 26.90% | ||
Alcohol | 0.209 | 0.464 | ||||
No | 41 (41.8) | 24 (6–120) | 46.30% | 34.10% | ||
Yes | 57 (58.2) | 25 (3–98) | 28.10% | 24.60% | ||
Differentiation | < 0.001* | 0.001* | ||||
Highly | 32 (32.7) | 42.5 (8–120) | 46.90% | 37.50% | ||
Medium | 33 (33.7) | 27 (6–85) | 33.30% | 24.20% | ||
Low | 33 (33.7) | 15 (3–89) | 27.30% | 24.20% | ||
Invasion direction | 0.003* | < 0.001* | ||||
Up | 43 (56.1) | 15 (3–89) | 45.50% | 38.20% | ||
Down | 55 (43.9) | 32 (3–120) | 23.30% | 16.30% | ||
T stage | 0.002* | 0.057 | ||||
T1 | 3 (3.1) | 67 (31–120) | 100.00% | 75.00% | ||
T2 | 14 (14.3) | 39.5 (9–95) | 57.10% | 42.90% | ||
T3 | 37 (37.8) | 27 (6–120) | 37.80% | 27.80% | ||
T4 | 44 (44.9) | 18.5 (3–76) | 22.70% | 20.50% | ||
N stage | 0.002* | 0.022* | ||||
N0 | 75 (76.5) | 32 (3–120) | 40.00% | 29.30% | ||
N1 | 4 (4.1) | 12 (5–17) | 0% | 0% | ||
N2 | 19 (19.4) | 13 (3–89) | 26.30% | 31.60% | ||
M stage | 0.531 | 0.108 | ||||
M0 | 95 (95.9) | 25 (3–120) | 35.80% | 29.50% | ||
M1 | 3 (4.1) | 15.5 (3–32) | 33.30% | 0.00% | ||
Clinical stage | 0.015* | 0.034* | ||||
I | 3 (3.1) | 67 (31–120) | 100.00% | 100.00% | ||
II | 9 (9.2) | 54 (10–95) | 50.00% | 40.00% | ||
III | 28 (28.6) | 29.5 (8–98) | 42.90% | 28.60% | ||
IV | 58 (59.2) | 19 (3–120) | 26.30% | 22.80% |
Therapeutic procedure
Therapeutic outcomes of MSSCC patients
Characteristic | OS | P Value | DFS | P Value |
---|---|---|---|---|
HR (95% CI) | HR (95% CI) | |||
Smoking | ||||
No | [Reference] 1 | [Reference] 1 | ||
Yes | 2.098(1.140–3.862) | 0.017* | NA | 0.377 |
Differentiation | ||||
Highly | [Reference] 1 | [Reference] 1 | ||
Medium | 1.784 (0.936–3.398) | 0.078 | 1.648(0.909–2.988) | 0.1 |
Low | 3.473 (1.793–6.725) | < 0.001* | 2.970(1.597–5.524) | 0.001* |
T stage | ||||
T1 | [Reference] 1 | [Reference] 1 | ||
T2 | 0.711 (0.277–1.824) | 0.479 | NA | 0.336 |
T3 | 0.439 (0.146–1.325) | 0.144 | NA | 0.928 |
T4 | 2.454 (1.099–5.477) | 0.028* | NA | 0.059 |
N stage | ||||
N0 | [Reference] 1 | [Reference] 1 | ||
N1 | NA | 0.192 | 3.400(1.068–10.828) | 0.038* |
N2 | NA | 0.148 | 1.742(0.738–4.116) | 0.205 |
M stage | ||||
M0 | [Reference] 1 | [Reference] 1 | ||
M1 | NA | 0.248 | NA | 0.046 |
Clinical stage | ||||
I | [Reference] 1 | [Reference] 1 | ||
II | NA | 0.346 | NA | 0.883 |
III | NA | 0.267 | NA | 0.798 |
IV | NA | 0.663 | NA | 0.167 |
Treatment | ||||
SUR | [Reference] 1 | [Reference] 1 | ||
SUR+CT/RT | 0.853 (0.319–2.270) | 0.751 | 0.852(0.336–2.161) | 0.736 |
CT/RT+SUR | 0.369 (0.107–1.267) | 0.113 | 0.510(0.167–1.551) | 0.235 |
NON-SUR | 1.054 (0.381–2.919) | 0.919 | 0.910(0.315–2.362) | 0.846 |